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Abstract
Background—Financial concerns are often cited by physicians as a barrier to administering 
routinely recommended vaccines to adults. The purpose of this study was to assess (1) perceived 
payments and profit from administering recommended adult vaccines and (2) vaccine purchasing 
practices among general internal medicine (GIM) and family medicine (FM) practices in the 
United States.
Methods—We conducted an interviewer-administered survey from January–June 2014 of 
practices stratified by specialty (FM or GIM), affiliation (standalone or ≥2 practice sites), and level 
of financial decision-making (independent or larger system level) in FM and GIM practices that 
responded to a previous survey on adult vaccine financing and provided contact information for 
follow-up. Practice personnel identified as knowledgeable about vaccine financing and billing 
responded to questions about payments relative to vaccine purchase price and payment for vaccine 
administration, perceived profit on vaccination, claim denial, and utilization of various purchasing 
strategies for private vaccine stocks. Survey items on payment and perceived profit were assessed 
for various public and private payer types. Descriptive statistics were calculated and responses 
compared by physician specialty, practice affiliation, and level of financial decision-making
Corresponding author: Megan C. Lindley, MPH, Centers for Disease Control and Prevention, Immunization Services Division, 1600 
Clifton Road NE, Mailstop A-19, Atlanta, GA 30329. 404-639-8717. MLindley@cdc.gov.
At the time of the study, Ms. Snow was employed by the Adult and Child Consortium for Health Outcomes Research and Delivery 
Science at University of Colorado Anschutz Medical Campus in Aurora, CO.
HHS Public Access
Author manuscript
Vaccine. Author manuscript; available in PMC 2019 February 14.
Published in final edited form as:
Vaccine. 2018 February 14; 36(8): 1093–1100. doi:10.1016/j.vaccine.2018.01.015.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Results—Of 242 practices approached, 43% (n=104) completed the survey. Reported payment 
levels and perceived profit varied by payer type. Only for preferred provider organizations did a 
plurality of respondents report profiting on adult vaccination services. Over half of respondents 
reported losing money vaccinating adult Medicaid beneficiaries. One-quarter to one-third of 
respondents reported not knowing about Medicare Part D payment levels for vaccine purchase and 
vaccine administration, respectively. Few respondents reported negotiating with manufacturers or 
insurance plans on vaccine purchase prices or payments for vaccination.
Conclusions—Practices vaccinating adults may benefit from education and technical assistance 
related to vaccine financing and billing and greater use of purchasing strategies to decrease upfront 
vaccine cost.
Keywords
adult immunization; vaccine financing; vaccine billing; survey research
The Advisory Committee on Immunization Practices (ACIP) recommends routine 
administration of several vaccines for U.S. adults, based on age and other risk factors. 
Coverage for adult vaccines is well below Healthy People 2020 targets.(1) Barriers to adult 
vaccination reported by patients and healthcare providers include not knowing vaccines are 
needed, other issues taking precedence during brief medical visits, and physicians not 
recommending vaccination. Cost-related barriers including inadequate payments for 
vaccination services are the most common barriers to adult vaccination reported by 
physicians.(2–6) Purchase prices for vaccines routinely recommended for adults range from 
$16 to over $200 per dose in the private sector.(7)
Physicians providing care to both publicly- and privately-insured patients may receive 
widely divergent payments for administering the same vaccine depending on the patient’s 
insurance benefits. Generally, private insurance plans establish set payments for vaccine 
purchase and administration. Providers contracting with the plan agree to accept these rates, 
although negotiation is possible.(8) Most plans specify provider types and sites of care for 
which vaccination is covered; payments may vary by provider and site. Payments under 
original Medicare (Part B), which covers influenza and pneumococcal vaccination, hepatitis 
B vaccination for certain at-risk persons, and tetanus vaccination for wound care only, are 
established at the federal level with geographic adjustments.(9) Medicaid fee-for-service 
payments are determined by each state.(10) For Medicare Part D, a prescription drug benefit 
that covers all ACIP-recommended vaccines not covered under Part B, the payment structure 
is similar to private insurance: multiple Part D plans operate in each state and each plan 
establishes payments for vaccination. Medicaid managed care plans operate similarly.
The Patient Protection and Affordable Care Act of 2010 (ACA) includes several elements 
designed to increase access to preventive services including vaccines. The ACA requires 
coverage for ACIP-recommended vaccines with no patient cost-sharing when vaccines are 
administered by in-network providers to beneficiaries of non-grandfathered private health 
plans or Medicaid beneficiaries who gained eligibility through ACA program expansions.
(11) (In 2016, 77% of workers with employer-based health insurance were covered by non-
grandfathered plans.)(12) It also specified a temporary increase in Medicaid payments for 
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certain primary care services, including vaccine administration, provided by certain types of 
physicians; services provided from January 1, 2013–December 31, 2014 were paid at the 
lower of the provider’s actual charge for the service or the respective Medicare Part B fee 
schedule rate, which is substantially greater than Medicaid vaccine administration payments 
in most states.(10,13–14) The ACA does not include provisions related to private insurance 
payments to physicians or physician practices for vaccination, nor make any significant 
changes to vaccination benefits coverage or payment rates for Medicare beneficiaries or 
persons who were Medicaid-eligible prior to the ACA Medicaid expansion that began in 
January 2014.
In 2013, we conducted a survey on adult vaccination billing and financing among family 
medicine (FM) and general internal medicine (GIM) physicians.(15) Significant proportions 
of respondents reported being unable to answer questions on vaccine purchase and 
administration payments. Since financial concerns are a commonly-reported barrier to adult 
vaccination, we designed the current study to better understand vaccine financing issues in 
physician practices serving adult patients. Our primary objectives were to assess among 
knowledgeable practice staff (1) perceived payments and profit from administering vaccines 
routinely recommended for adults and (2) vaccine financing and purchasing practices among 
FM and GIM in the U.S.
Methods
Study design
The study comprised a telephone survey of personnel working in FM and GIM practices 
who were considered knowledgeable about vaccine financing and billing. The 553 of 839 
physicians (66%) that responded to our previous survey (15) were asked to provide contact 
information for someone at their practice who had direct experience with vaccine billing and 
could report the practice’s vaccine financing experiences. Overall, 47% of respondents to the 
previous survey (262/553) provided contact information consisting of at least one of the 
following: email address, telephone number, or mailing address.
The 262 eligible practices were stratified based on specialty (FM or GIM), affiliation 
(standalone practice or ≥2 practice sites, hereinafter ‘multisite practices’), and level of 
financial decision-making (independent or system). The latter factors were examined 
because being one of multiple sites or belonging to a healthcare system may affect the level 
at which purchasing decisions are made – and thus, respondents’ knowledge of these 
decisions – as well as a practice’s ability to obtain more favorable pricing or payments based 
on volume of vaccines administered. We used a quota sampling approach to select practices 
similar to those responding to our previous survey. First, we established proportional 
sampling targets based on the number of responses to the previous survey that fell into each 
of eight specialty/affiliation/decision-making categories. Then, practices in each category for 
which contact information was provided were approached at random until the target was 
reached (two of eight categories) or all eligible practices were exhausted (six of eight 
categories) (Appendix).
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Study participants
Individuals were contacted first via e-mail if provided or U.S. mail otherwise to schedule the 
interviewer-administered survey. Following the first contact, individuals received up to four 
contact attempts via telephone interspersed with up to three attempts via e-mail or U.S. mail. 
(Study personnel looked up telephone numbers and mailing addresses for practices that did 
not provide this information.) If no response was received after these attempts, the physician 
who provided the contact information was contacted via U.S. mail to request participation of 
another staff member. Successfully contacted individuals were asked to provide a telephone 
number and date/time to complete the survey.
The survey was administered January-June 2014. Participants received $75 for their time. 
The survey was deemed exempt research by the University of Colorado’s Institutional 
Review Board.
Measurements
The survey asked about the respondent’s position and involvement in vaccine purchasing 
and billing for the practice, whether and how the practice bills Medicare Part D, and what 
percentage of the practice’s annual budget goes to adult vaccines. It also included four sets 
of questions about respondents’ experiences with six payer types: private fee-for-service 
insurance (FFS), private preferred provider organizations (PPO), private health maintenance 
or managed care organizations (HMO/MCO), Medicaid, Medicare Part B, and Medicare Part 
D. For each payer, respondents reported payment relative to vaccine purchase prices (less 
than, about the same, more than); general administration payment for the first vaccine given 
in a visit (<$11, $11–$17, $18–$24, >$24, too variable to answer); perceived profit on 
vaccination services (lose money, break even, make a profit); and frequency of claim denial 
for any reason (frequently, sometimes, rarely, never). The question on perceived profit was 
also asked about patients who pay out of pocket for vaccination. Respondents were asked to 
assess profit margin “taking into account what you pay to purchase vaccines, your 
administration costs, and what you are reimbursed for vaccine cost and administration”. For 
each question set, respondents could report “don’t know” or “don’t see patients with this 
insurance type”.
Respondents were asked about methods used to purchase private vaccine stocks and to 
negotiate with private insurance plans regarding vaccination payments. They were also asked 
whether the practice had stopped purchasing any vaccines for adults, or had stopped 
vaccinating patients with a particular type of health insurance, due to financial concerns. For 
all items, respondents were instructed to answer with respect to vaccines routinely 
recommended for adults ≥19 years other than influenza (i.e. excluding travel vaccines and 
those given only to pediatric patients). Respondents reported their overall profit margin for 
seasonal influenza vaccination and non-influenza vaccines separately.
Analysis
Descriptive statistics were calculated using SAS version 9.4; Mantel-Haenszel chi square 
and Fisher’s Exact tests were used to compare responses by specialty, affiliation, and level of 
financial decision-making. For most items, responses did not differ significantly between 
Lindley et al. Page 4
Vaccine. Author manuscript; available in PMC 2019 February 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FM and GIM; therefore, we present results for both specialties combined. Where responses 
differed by specialty, we present comparisons and p-values. Results were similar whether 
analyzed by affiliation or decision-making level; we present findings by affiliation. Findings 
for specific payer types are restricted to practices reporting they saw patients with, and 
billed, that insurance.
Results
Description of respondents
Based on predetermined recruitment targets, we approached 242 practices for which we had 
contact information. Of these, 31 (13%) refused participation and 107 (44%) could not be 
reached. Staff from 104 practices (43%) completed the survey. The majority of respondents 
(52%) were office managers or health administrators, 25% were billing staff, and 14% were 
clinicians. (Table 1) The majority reported submitting vaccine claims or supervising 
individuals who submit claims, or both; slightly under one-third reported participating in 
contract negotiations for vaccine purchase or insurance payment. Claims submission and 
negotiation were more commonly reported by standalone versus multisite practices. Sixty-
two percent of respondents reported participating in decisions about which vaccines to stock. 
Only 38% reported billing Medicare Part D for adult vaccines, and only 16% reported using 
TransactRx, which facilitates Part D claims submission by physicians.
Payments for vaccination
For each private payer type, about half of respondents reported payment “about the same” as 
vaccine purchase price (Table 2). Smaller proportions reported payment similar to purchase 
prices for public payers; Medicaid was the only payer for which the majority of respondents 
(60%) reported payment less than purchase price. Notably, 26% of respondents said “don’t 
know” when asked about Medicare Part D payments vs. <3% for all other payers. There 
were no significant differences in response by affiliation.
When asked about vaccine administration payment (Table 3), a payment range of $11–$17 
was reported by about one-third of respondents (31%–34%) for each private payer type and 
by 26% for Medicare Part B. Medicaid was the only payer for which the majority of 
respondents (54%) reported vaccine administration payment <$11. For Medicare Part D, 
equal proportions (18%) reported payments of <$11 and $11–$17; however, one-third of 
respondents reported not knowing about vaccine administration payment. For all insurance 
types except Medicare Part B and Medicaid, ≥10% of respondents said payments were too 
variable to answer the question.
Perceived profit and claim denial
Perceived profit from vaccination varied substantially by payer (Figure 1). The largest 
proportions of respondents perceived making a profit under FFS and PPO plans and from 
patients paying out-of-pocket; less than one-third of respondents seeing patients in HMO/
MCOs, Medicaid, or Medicare reported profiting on vaccinations. PPOs were the only payer 
for which a plurality of respondents reported making a profit; the most common response 
was “break even” for FFS, HMO/MCO, out-of-pocket, and Medicare Part B. Equal 
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proportions of respondents (33%) selected “break even” and “don’t know” when asked about 
vaccination under Medicare Part D. Over half (55%) of respondents reported losing money 
administering vaccines to Medicaid patients. Taking into account all payer types, fewer than 
10% of respondents said they lost money administering vaccines; 37% reported making a 
profit administering non-influenza vaccines and 50% on seasonal influenza vaccination.
When asked how profit margin for vaccine delivery changed in the past several years, 40% 
said it stayed the same and 31% said it decreased, while 17% said it increased and 12% did 
not know. No differences in perceived change in profit margin were noted by affiliation, but 
FM were less likely than GIM to report decreased profit margin (21% vs. 40%, p<0.05) and 
more likely to respond “don’t know” (19% vs. 4%, p<0.05). About one-third of respondents 
(31%–38%) reported claims being “frequently” or “sometimes” denied for any reason by 
most payers. For Medicare Part D, only 24% reported frequent/sometime claim denial, but a 
higher proportion of respondents (36%) answered “don’t know” than for other payers.
Vaccine purchasing practices
Reported frequency of vaccine purchasing and negotiation activities for privately insured 
patients varied widely between standalone and multisite practices for all items assessed 
(Table 4). Strategies most commonly reported by respondents were purchasing from vaccine 
manufacturers using bulk ordering discounts (60% reported frequently/sometimes doing 
this), participating in group purchasing organizations for vaccines (59%), and utilizing 
prompt pay discounts (51%). About one-quarter of respondents reported frequently or 
sometimes negotiating payments for vaccines or vaccine administration with insurance 
plans.
Recent changes in vaccine provision
When queried about the past 12 months, 8% of practices reported they stopped purchasing 
one or more vaccines for adults and 11% reported they stopped giving certain vaccines to 
patients with particular types of health insurance due to financial concerns, with no 
differences by affiliation.
Discussion
In this survey of physician practices, perceived payment levels and profit margins for adult 
vaccination varied widely by payer type. Practices most often reported breaking even on 
adult vaccination, however the majority perceived financial loss from vaccinating adult 
Medicaid beneficiaries. Under half of surveyed practices reported billing Part D for 
vaccinations; less than one-quarter reported routinely negotiating vaccination payments with 
private insurers. Low utilization of many payment-maximizing strategies, concerns about 
Medicaid payments, and continued difficulty billing Medicare Part D likely contribute to the 
perception that vaccinating adults is not profitable for many practices.
Among payer types examined, only PPOs were identified by a plurality of respondents as 
providing adequate payment to make a profit once vaccination-related costs were taken into 
account. Although we measured only perceived payments, previous research in pediatric 
practices found public and private health plans’ payments for vaccine administration often 
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did not cover the variable costs of vaccination.(16) The financial feasibility of administering 
vaccines to adults likely depends on the payer mix in a given practice. Simply breaking even 
may not provide adequate incentive for physicians to stock and administer vaccines, which 
pose unique challenges and start-up costs to practices.(17) Vaccine acquisition costs and 
time to administer and record vaccinations also may affect profit, yet few practices reported 
regularly negotiating with manufacturers or insurers to reduce vaccine purchase costs or 
increase payments. It is unclear whether practices are unaware of these strategies or 
previously employed these strategies but ceased due to a failure to obtain cost savings. 
Access to discounted vaccine pricing via participation in purchasing groups (reported by 
59% of respondents) may obviate the need to negotiate directly with manufacturers.(18)
Half of respondents administering influenza vaccine to adults reported making a profit 
compared with 37% of respondents administering non-influenza vaccines. Influenza 
vaccines are relatively less expensive than other routinely administered adult vaccines (7), 
recommended for adults of all ages and health conditions, and ordered and administered 
annually. Other adult vaccines are less commonly stocked by physicians, particularly GIM, 
whose patient panels do not include pediatric populations that would routinely receive these 
vaccines.(4) Physicians may have less experience billing for non-influenza vaccines and may 
purchase fewer doses for their adult patients, precluding volume ordering discounts. 
Notably, many vaccine purchasing groups provide discounts even for small-volume 
purchases; purchasing group participation was common among both FM and GIM 
respondents.(18)
Previous studies showed a lack of knowledge among physicians about Medicare Part D 
vaccination benefits, corroborating our findings.(3,15,19) This is troubling as Part D is 
intended to cover all recommended vaccines not covered by Medicare Part B, including 
Tdap and zoster, for which uptake among older adults is low.(1) Provider recommendation is 
an important predictor of vaccination and standardized vaccination offering may reduce 
persistent racial/ethnic disparities in adult vaccination uptake (20), yet imperfect 
understanding of vaccination benefits or perceived inadequate payments may discourage 
physicians from recommending vaccines to their adult patients.(15,21) One study showed 
FM and GIM prioritize influenza and pneumococcal vaccines over Tdap and zoster and 
speculated that difficulties billing Medicare Part D accounted for this finding.(22) Although 
the majority of physicians report stocking vaccines covered by Part D (4), some practices 
may provide these vaccines only to privately insured patients and refer Medicare 
beneficiaries for vaccination elsewhere.(22) A 2011 report from the U.S. Government 
Accountability Office recommended that the Centers for Medicare & Medicaid Services 
(CMS) take steps to alleviate administrative challenges to physicians related to Medicare 
Part D vaccination benefits; the following year, CMS changed Part D formulary designs to 
encourage offering low- or no-cost vaccinations.(19) Nonetheless, our findings indicate 
continued challenges implementing billing for the pharmacy-focused Part D plans in 
medical practices.
Strengths of this study include selection of practices to elucidate previous findings (15) and 
capture variations likely to impact vaccine financing experiences, such as affiliation with 
multiple sites and membership in a larger organization. Limitations include that data were 
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self-reported and may not accurately reflect practices’ income from payers. For example, 
48% of respondents reported vaccine administration payments <$18 from Medicare Part B, 
but the national average Part B payment for vaccine administration in 2013 was $25.86.(23) 
Nevertheless, perceived payment and profit are important as this may affect how practices 
choose to provide vaccines to patients. Our participation rate was suboptimal, and sampling 
focused on factors of interest rather than generalizability, so respondents may not be 
representative of all FM and GIM in the U.S. Practices that chose to complete our survey 
may have different experiences with vaccine financing than those not participating. All 
practices were part of an existing survey network to explore vaccine-related issues; prior 
work suggests network physicians’ responses are similar to those of randomly-selected 
physicians. (24) We did not assess respondents’ vaccine stocking practices, which may 
influence their perceptions of vaccine financing and reimbursement. Finally, quantitative 
data support physicians’ general perception of low reimbursement for vaccinating Medicaid 
beneficiaries, but payment rates are established by states and vary from under two dollars to 
over $30.(10) Our sample size was insufficient to evaluate perceived payment adequacy at 
the state level.
These findings generally corroborate those of our prior survey, in which physicians reported 
some level of dissatisfaction with all payers, but particularly Medicare and Medicaid.(15) 
Similar findings were observed among pediatricians with respect to vaccine administration 
payments.(25) A persistent lack of knowledge about Medicare vaccination benefits and 
perceived financial loss from Medicaid could adversely affect provider willingness to 
vaccinate publicly insured adults, leading to lower vaccination coverage in this population.
(1) CMS issued guidance for physicians in 2007 on how to bill Part D for vaccinations (26), 
yet our study and others show continued confusion related to Part D. Organizations 
representing physicians who treat adult patients are well-positioned to disseminate CMS 
guidance and provide member education on business practices to mitigate financial burdens 
of vaccination. The National Adult and Influenza Immunization Summit recently released 
guidance and resources on vaccine coding and billing that includes information from several 
national physician groups.(27) Studies by academic or government partners could provide 
valuable data about the cost to vaccinate adults in various public and private settings and 
geographic regions; physicians may wish to share observations about their costs of 
vaccination during scheduled negotiations with insurance plans. Without data on practices’ 
costs to vaccinate adults, insurers cannot evaluate whether vaccination services payments are 
adequate to compensate physicians for their time and expenses. Finally, public and private 
stakeholders could collaborate to increase physicians’ ease of billing Medicare Part D for 
vaccinations.
Few practices in our study reported ceasing to provide vaccines to adult patients for financial 
reasons, consistent with a 2009 study.(17) However, physicians who do not stock a given 
vaccine may also be less likely to assess patients’ needs for that vaccine.(4) Even a small 
reduction in practice-based vaccine access is concerning given suboptimal adult vaccination 
coverage and the importance of provider recommendations and offers to optimize vaccine 
uptake.(6, 28) Despite practices’ apparent willingness to continue vaccinating adults for 
limited financial gain, achieving national goals related to improving vaccine access for 
adults (29) could be facilitated if targeted information regarding vaccine financing and 
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billing strategies, and assistance implementing the strategies most appropriate to their 
practices, were available to physicians. Interventions assisting practices to reduce 
vaccination-associated expenses and obtain full payment for vaccines administered, and to 
develop referral systems when it is not feasible to offer certain vaccines, could strengthen 
the U.S. adult vaccination infrastructure and improve access to all ACIP-recommended 
vaccines for adults.
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Figure 1. Perceived level of profit for vaccination by insurance type and overall*
FFS: Fee-for-Service; PPO: Preferred Provider Organization; HMO/MCO: Health 
Maintenance Organization/Managed Care Organization
* For each type of insurance product, responses are restricted to practices reporting seeing 
patients with that type of insurance and billing that type of insurance.
General internal medicine respondents were more likely than family medicine respondents 
to report breaking even on Medicare Part B vaccination (p<0.05). Multisite practices were 
more likely than standalone to report breaking even on Medicare Part B vaccinations, while 
standalone practices were more likely to report making a profit (p < 0.005). Multisite 
practices were more likely than standalone practices to report breaking even, and less likely 
to report making a profit, on all non-influenza vaccines (p < 0.005) and less likely than 
standalone practices to report making a profit on seasonal influenza vaccination (p < 0.05).
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